NasdaqGS:PETS

Stock Analysis Report

Executive Summary

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States.

Snowflake

Fundamentals

Flawless balance sheet established dividend payer.


Similar Companies

Share Price & News

How has PetMed Express's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.2%

PETS

4.4%

US Online Retail

2.3%

US Market


1 Year Return

-34.0%

PETS

6.5%

US Online Retail

5.6%

US Market

Return vs Industry: PETS underperformed the US Online Retail industry which returned 6.5% over the past year.

Return vs Market: PETS underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

PETSIndustryMarket
7 Day2.2%4.4%2.3%
30 Day4.8%-1.9%-1.0%
90 Day16.8%-5.1%-0.7%
1 Year-30.6%-34.0%6.5%6.5%7.9%5.6%
3 Year1.0%-9.0%79.9%79.7%45.6%36.3%
5 Year83.2%51.4%177.5%165.8%65.8%47.6%

Price Volatility Vs. Market

How volatile is PetMed Express's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PetMed Express undervalued compared to its fair value and its price relative to the market?

12.73x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: PETS ($19.02) is trading above our estimate of fair value ($15.07)

Significantly Undervalued: PETS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PETS is good value based on its PE Ratio (12.7x) compared to the Online Retail industry average (33.1x).

PE vs Market: PETS is good value based on its PE Ratio (12.7x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: PETS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PETS is overvalued based on its PB Ratio (3.1x) compared to the US Online Retail industry average (2.5x).


Next Steps

Future Growth

How is PetMed Express forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-0.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PETS's earnings are forecast to decline over the next 3 years (-0.2% per year).

Earnings vs Market: PETS's earnings are forecast to decline over the next 3 years (-0.2% per year).

High Growth Earnings: PETS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PETS's revenue (1.7% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: PETS's revenue (1.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if PETS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has PetMed Express performed over the past 5 years?

19.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PETS's earnings have grown by 19.6% per year over the past 5 years.

Accelerating Growth: PETS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PETS had negative earnings growth (-24.9%) over the past year, making it difficult to compare to the Online Retail industry average (-15.1%).


Return on Equity

High ROE: PETS's Return on Equity (24.7%) is considered high.


Return on Assets

ROA vs Industry: PETS has a higher Return on Assets than the Online Retail industry average last year.


Return on Capital Employed

ROCE Improving: PETS's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is PetMed Express's financial position?


Financial Position Analysis

Short Term Liabilities: PETS's short term assets ($117.2M) exceeds its short term liabilities ($20.3M)

Long Term Liabilities: PETS's short term assets (117.2M) exceeds its long term liabilities (939.0K)


Debt to Equity History and Analysis

Debt Level: PETS is debt free.

Reducing Debt: PETS has not had any debt for past 5 years.

Debt Coverage: PETS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PETS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: PETS has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PETS's debt is covered by short term assets.


Next Steps

Dividend

What is PetMed Express's current dividend yield, its reliability and sustainability?

5.68%

Current Dividend Yield


Dividend Yield vs Market

company5.7%marketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Years5.9%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: PETS's dividend (5.68%) is higher than the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: PETS's dividend (5.68%) is in the top 25% of dividend payers in the US market (3.76%)

Stable Dividend: PETS's dividends per share have been stable in the past 10 years.

Growing Dividend: PETS's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (72.3%), PETS's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of PetMed Express's salary, the management and board of directors tenure and is there insider trading?

16.5yrs

Average board tenure


CEO

Menderes Akdag (58yo)

18.6yrs

Tenure

US$857,551

Compensation

Mr. Menderes Akdag has been the Chief Executive Officer of PetMed Express, Inc. since March 16, 2001 and has been its President since August 2005. Mr. Akdag has a breadth of experience in the areas of dire ...


CEO Compensation Analysis

Compensation vs. Market: Menderes's total compensation ($USD857.55K) is about average for companies of similar size in the US market ($USD1.82M).

Compensation vs Earnings: Menderes's compensation has been consistent with company performance over the past year.


Board Age and Tenure

16.5yrs

Average Tenure

72yo

Average Age

Experienced Board: PETS's board of directors are seasoned and experienced ( 16.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Menderes Akdag (58yo)

    CEO, President & Director

    • Tenure: 18.6yrs
    • Compensation: US$857.55k
  • Bruce Rosenbloom (50yo)

    CFO & Treasurer

    • Tenure: 18.4yrs
    • Compensation: US$866.28k
  • Alison Berges

    Corporate Secretary & General Counsel

    • Tenure: 0yrs

Board Members

  • Gian Fulgoni (71yo)

    Independent Director

    • Tenure: 16.9yrs
    • Compensation: US$305.73k
  • Menderes Akdag (58yo)

    CEO, President & Director

    • Tenure: 18.6yrs
    • Compensation: US$857.55k
  • Ronald Korn (79yo)

    Independent Director

    • Tenure: 16.9yrs
    • Compensation: US$305.73k
  • Bob Schweitzer (73yo)

    Independent Chairman

    • Tenure: 13.3yrs
    • Compensation: US$305.73k
  • Frank Formica (75yo)

    Independent Director

    • Tenure: 16.2yrs
    • Compensation: US$305.73k
  • Leslie C. Campbell (61yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$305.73k

Company Information

PetMed Express, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PetMed Express, Inc.
  • Ticker: PETS
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Internet and Direct Marketing Retail
  • Sector: Retail
  • Market Cap: US$380.874m
  • Shares outstanding: 20.02m
  • Website: https://www.1800petmeds.com

Number of Employees


Location

  • PetMed Express, Inc.
  • 420 South Congress Avenue
  • Delray Beach
  • Florida
  • 33445
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PETSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 1997
PQMDB (Deutsche Boerse AG)YesCommon StockDEEURSep 1997

Biography

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:41
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.